ABSTRACT
INTRODUCTION

53
Calcitonin gene-related peptide (CGRP) decreases blood pressure, increases heart rate 54 and has a positive-inotropic effect in humans (9; 14). CGRP is expressed in ventricular sensory approximately 30% of basal coronary blood flow (Kubota et al 1985) . Previous studies from our 66 laboratory have demonstrated a predilection for hypertension in CGRP knockout mice (12) .
67
Moreover, acute administration of CGRP 8-37 produces a hypertensive effect in L-NAME-treated 68 rats during pregnancy when sex steroid hormone levels are increased, an effect not observed 69 postpartum (11; 13). hypertrophy (1) . Moreover, increased plasma levels of CGRP are associated with these 85 complications of cardiovascular disease (8; 14). We have previously reported that estradiol and 86 progesterone enhance CGRP-induced contractile effects in vascular smooth muscle, and we sought to 87 consolidate these findings in the heart (10-12). The present study was, therefore, designed to 93 kept under secure, clean and controlled room temperature (70°F-74°F) with a 6:00 h to 18:00 h 100 light cycle and were fed food and water ad libitum.
MATERIALS AND METHODS
92
Conformity statement
All the procedures conform to the Guide for the Care and Use of Laboratory Animals
101
Isolation of Cardiomyocytes
102
All the reagents were purchased from Sigma Chemicals (St. Louis, MO). Double-103 distilled water from a MilliQ system (Millipore Corporation, MA) was used to prepare all 104 solutions. Prepared solutions were oxygenated for 20 min prior to perfusion with 5%CO 2 -95% 0 2 105 and pH at 7.4 with HCl or NaOH.
106
Animals were injected with sodium heparin (1000 U/kg, i.p.) and anesthetized with 107 pentobarbital sodium (40 mg/kg, i.p.), 30 min prior to removal of the heart. After excision, the 108 heart was quickly transferred to a Langendorff setup for 5 min retrograde coronary perfusion protease type XIV (Sigma, MO) were added for the last 10 min. Then, the heart was cut, minced 114 and filtered in a buffer solution containing (mM): 113 NaCl, 4. 
Inotropic measurements in vitro
119
The contractile properties of the cardiomyocytes were assessed at the cellular and 120 sarcomere levels simultaneously, with the dynamic changes in intracellular calcium using the 
Pressure-volume loop acquisition
139
Initially, rats were anesthetized using halothane inhalation for tracheal intubation. The 140 endotracheal tube was then connected to a mechanical ventilator for continuous delivery of 1-2% 141 halothane with oxygen-enriched room air. A dissection of the diaphragm exposed the apex of the 142 heart where a 26-gauge needle was briefly inserted to introduce a conductance catheter (1. , CGRP 8-37 and LY294002.
160
The syringe concentrations were adjusted to the flow rate of 0.2 μl/min in order to achieve a 
RESULTS
199
Effects of CGRP on Cardiac Myocytes in vitro 200
Mechanisms of the inotropic and lusitropic effects of CGRP on the sarcomere 201 Baseline resting sarcomere length did not change significantly within the test time frame.
202
However, addition of CGRP 1-37 increased the baseline sarcomere length by 7.9 ± 0.2 % (p<0.01). on the rate of sarcomeric relaxation were not significantly affected by CGRP 8-37 ; however, this 210 relaxation was blocked by inhibition of PI3K signaling using LY294002. (30.36 ± 6.60%; p<0.05), cellular shortening (36.87 ± 9.83%; p<0.01), and the cellular relaxation 233 rate constant (28.25 ± 18.63%; p<0.05); progesterone had no effect. In the presence of 17β-234 estradiol, the positive-inotropic effects of CGRP 1-37 were augmented (contraction velocity by 235 27.43 ± 11.67% and cell shortening by 24.31 ± 7.36%, respectively; p<0.01) and the lusitropic 236 effects of CGRP were attenuated (39.42 ± 13.25%; p<0.01). Figure 9 shows that combination treatment with 17β-estradiol plus progesterone 247 augmented the calcium response to CGRP . In the presence of CGRP 
PI3K-dependence of CGRP-induced inotropic and lusitropic effects in vivo
294
To test whether the inotropic effects observed in vivo were mediated by PI3K/Akt, 
CGRP-Induced Inotropy
321
This study is the first to show that CGRP 1-37 , independent of its known vasodilatory 322 effects, has positive-inotropic effects on the heart, partially mediated by PI3K signaling. The 
Estrogenic Effects of CGRP-Induced Inotropy
335
The results of this study show that 17β-estradiol decreased the heart's sarcomeric and 336 cellular inotropy whereas progesterone had no effect. 17β-estradiol is also reported to decrease 337 cellular contractility in human and mouse male cardiomyocytes, but not in female 338 cardiomyocytes (21). This male gender-specific negative-inotropic effect is attributed to activity 
388
The PVA is directly related to the amount of oxygen consumption by the left ventricle per beat.
389
Thus, it appears that CGRP enabled the left ventricle to produce greater ejection fractions at 390 lower energy costs. This is a significant finding in view of a report that CGRP is released from 391 ex-vivo pig hearts as a consequence of ischemia/reperfusion (33) . Taken together, these findings 392 suggest that CGRP promotes restoration of cardiac function with a small expenditure of energy.
393
In the present study, all of the effects of CGRP occurred with no significant change in EDPVR or or mechanical elements at basal levels. PI3K inhibition was effective in reversing the CGRP1-411 37 effects on the cellular and whole heart levels but not effectively on the sarcomere. The 412 CGRP-induced sarcomere effects on the relaxation rate constant were reversed by PI3K
413
inhibition similar to what we have found at the cellular and whole heart levels. However, the 414 sarcomeric shortening was not PI3K-dependent. The sarcomere being the basic elemental unit of 415 contractility, it is not unexpected that differences between sarcomere and cell or whole heart 416 preparations may exist due to other confounding factors found at higher architectural levels that 417 can intensify and amplify parameters found relevant at the cellular and whole organ levels. Our 418 group has also demonstrated and correlated the effects of CGRP on NO release by endothelial 419 cells with its strong vasodilatory effects. Because the heart has an endothelial lining, it is 420 expected that some CGRP-induced NO release may occur at the whole heart level but not with 421 the cardiomyocytes or sarcomere preparations. In view of the similarity we found in the 422 inotropic effects of CGRP on cardiomyocytes and the whole heart, it is reasonable to assume that 423 cardiac NO release does not significantly modulate the CGRP effects on the heart.
424
CGRP-Induced Effects on Compliance and Stroke Volume
425
One interesting aspect of the CGRP-induced positive-inotropy described herein is its 426 occurrence in conjunction with decrements in left ventricular stroke volume and compliance.
427
The increase in elastance indicates the need for a greater ESP to produce the same SV, and thus 428 reflects an increased rather than a decreased afterload. This is consistent with the reduced 
473
Conclusion
474
This multi-level study shows that CGRP 1-37 has positive inotropic but negative lusitropic 475 effects on the heart. These findings were consistent in t the sarcomere, cardiomyocyte and left 
